Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04000165 · ClinicalTrials.gov registry record · Early Phase 1
A Dose-Finding Study of AG-348 in Sickle Cell Disease
A Early Phase 1 study, sponsored by National Institutes of Health Clinical Center (CC).
- Completed
- Registry status
- Early Phase 1
- Development phase
- 17
- Enrollment target
NCT04000165 is a Early Phase 1 study that has completed, run by National Institutes of Health Clinical Center (CC). The registered enrollment target is 17 participants.
The verdict
NCT04000165, a Early Phase 1 study, has completed, sponsored by National Institutes of Health Clinical Center (CC).
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 17 participants
- Enrollment target
Study Summary
Background: Sickle Cell Disease (SCD) is an inherited blood disorder. People with SCD have abnormal hemoglobin in their red blood cells. Researchers are investigating the safety and efficacy of an investigational medicine called AG-348 (mitapivat sulfate) to determine if it will help people with SCD. Objective: To test the tolerability and safety of AG-348 in people with SCD. Eligibility: People ages 18 and older with SCD. Design: Participants will have 8 visits over approximately 14 weeks. At the first visit participants will be screened with a medical history, a physical exam, blood and urine testing, and an EKG. During the following 5 visits, participants will stay at the clinic for 1 night each. Participants will take study drug in increasing doses up to visit 6, after which the drug will be tapered off. All visits will include physical exam, blood, and urine tests. The last visit will occur 4 weeks after stopping the drug. Participants will provide DNA from the blood samples they provide. The DNA will be tested for an inherited gene that can cause differences in response to the study drug. Researchers may also test other genes to see if they can find any genes that interact with SCD.
Interventions
- DRUG AG-348
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2019-07-11 |
| Est. Completion | 2021-06-21 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04000165
The ClinicalTrials.gov registry entry for NCT04000165 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institutes of Health Clinical Center (CC), which has 338 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which AG-348 is the first listed.
NCT04000165 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04000165 about?
NCT04000165 is a clinical study titled "A Dose-Finding Study of AG-348 in Sickle Cell Disease". Background: Sickle Cell Disease (SCD) is an inherited blood disorder. People with SCD have abnormal hemoglobin in their red blood cells. Researchers are investigating the safety and efficacy of an investigational medicine called AG-348 (mitapivat sulfate) to determine if it will help people with SC...
What is the current status of trial NCT04000165?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 17 participants. The study started on 2019-07-11. Estimated completion is 2021-06-21.
What interventions are being tested in trial NCT04000165?
The interventions under investigation include: AG-348 (DRUG).
Who is sponsoring clinical trial NCT04000165?
This trial is sponsored by National Institutes of Health Clinical Center (CC), which has 338 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.